⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1559273 | 1.00 | — | — | |
| SCHEMBL1559274 | 1.00 | — | — | |
| SCHEMBL9068589 | 0.86 | — | — | |
| SCHEMBL15918329 | 0.77 | — | — | |
| SCHEMBL14638572 | 0.77 | CDA (0.35) | — | |
| SCHEMBL29397476 | 0.76 | KDM4E (0.50) | — | |
| SCHEMBL351949 | 0.74 | — | — | |
| SCHEMBL164603 | 0.74 | — | — | |
| SCHEMBL164602 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL20532011 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114149424-B | Heterocyclic compounds for the treatment of diseases | 奥比兰制药有限公司 | 2025-05-13 | — | — | CN | claimed |
| US-20260092064-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | OPPILAN PHARMA LTD. (GB) | 2026-04-02 | — | — | US | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| US-20250223290-A1 | AZAINDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2025-07-10 | — | — | US | disclosed |
| WO-2025128781-A1 | AZAINDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| CN-114149424-B | Heterocyclic compounds for the treatment of diseases | 奥比兰制药有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20240366615-A1 | POLQ INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 2024-11-07 | — | — | US | disclosed |
| WO-2024151993-A1 | PREPARATION OF AN S1P RECEPTOR MODULATOR | Oppilan Pharma Limited (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20140221373-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
| EP-2734516-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Boehringer Ingelheim International GmbH (DE) | 2014-05-28 | — | — | EP | disclosed |
| US-20140031339-A1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20140031339-A1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| WO-2013012844-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | WO | disclosed |
| US-8183281-B2 | CXC-chemokine receptor ligands | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| EP-2155670-B1 | ANTI -INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2012-04-18 | — | — | EP | disclosed |
| US-20100125071-A1 | CXC-CHEMOKINE RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| EP-2155670-A1 | ANTI -INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUNDS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008148790-A1 | ANTI -INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |